5,056 results match your criteria: "Paoli Calmettes Institute; INSERM UMR599 232 Bd[Affiliation]"
Cell Mol Gastroenterol Hepatol
March 2024
Centre de Recherche en Cancérologie de Marseille, CRCM, Marseille, France; Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France; Signaling, Hematopoiesis and Mechanism of Oncogenesis Lab, Marseille, France; OPALE Carnot Institute, Paris, France. Electronic address:
Cell Rep Med
December 2023
Childhood Cancer & Cell Death Team (C3 Team), LabEx DEVweCAN, Institut Convergence Plascan, Centre de Recherche en Cancérologie de Lyon (CRCL), Centre Léon Bérard, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, 69008 Lyon, France; Department of Translational Research in Pediatric Oncology PROSPECT, Centre Léon Bérard, 69008 Lyon, France. Electronic address:
Rhabdomyosarcoma (RMS) is the main form of pediatric soft-tissue sarcoma. Its cure rate has not notably improved in the last 20 years following relapse, and the lack of reliable preclinical models has hampered the design of new therapies. This is particularly true for highly heterogeneous fusion-negative RMS (FNRMS).
View Article and Find Full Text PDFBreast Cancer Res Treat
April 2024
Department of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, Canada.
Purpose: The interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC), with median progression-free survival (PFS) of 8.11 months, which was similar to that in the olaparib arm of the phase III OlympiAD trial (7.03 months).
View Article and Find Full Text PDFWorld J Gastrointest Surg
November 2023
Department of Digestive Surgical Oncology, Institut Paoli Calmettes, Marseille 13009, France.
Background: Rectal sparing is an option for some rectal cancers with complete or good response after chemoradiotherapy (CRT); however, it has never been evaluated in patients with metastases. We assessed long-term outcomes of a rectal-sparing approach in a liver-first strategy for patients with rectal cancer with resectable liver metastases.
Case Summary: We examined patients who underwent an organ-sparing approach for rectal cancer with synchronous liver metastases using a liver-first strategy during 2010-2015 ( = 8).
Clin Transl Radiat Oncol
January 2024
Department of Radiation Oncology, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.
Purpose: High-risk (HR) prostate cancer patients usually receive high-dose radiotherapy (RT) using a two-phase sequential technique, but data on a simultaneous integrated boost (SIB) technique are lacking. We prospectively evaluated the long-term results of urinary (GU) and digestive (GI) toxicity and survival data for high-dose RT using a SIB technique in HR and very high-risk (VHR) prostate cancer.
Methods: Patients were treated using an SIB technique in 34 fractions, at a dose of 54.
Therapie
February 2024
Galien Affaires, 75014 Paris, France.
This round table is the result of an observation. The observation being that controlled human infection clinical trials (also called "infectious challenge" trials or "Controlled Human Infection Models", "CHIM") recommended or even encouraged in the context of vaccine developments in particular, are not carried out in France. However, there are no formal prohibitions within regulations or ethical principles, which point to the prior assessment of risks and benefits for individuals and for society.
View Article and Find Full Text PDFBlood Adv
February 2024
Eurocord, Hopital Saint Louis, Assistance Publique - Hopitaux de Paris, Institut de Recherche de Saint-Louis EA3518, Université de Paris Cité, Paris, France.
To clarify the different characteristics and prognostic factors of cord blood transplantation (CBT) in adult patients with lymphoid neoplasms in Europe and Japan, we conducted a collaborative study. Patients aged 18-75 years receiving their first CBT (Europe: single CBT, n = 192; double CBT, n = 304; Japan: single CBT, n = 1150) in 2000-2017 were analyzed. Fewer patients with Hodgkin lymphoma (Europe vs Japan, 26% vs 5%), and older patients (≥50 years) (39% vs 59%) with a higher refined disease risk index (rDRI) (high-very high: 49% vs 14%) were included in the Japanese registry.
View Article and Find Full Text PDFBull Cancer
January 2024
Centre Léon-Bérard, hématologie clinique, Inserm U1052, Lyon, France; France Intergroupe de la leucémie myéloïde chronique Fi-LMC, France.
Nat Commun
December 2023
Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, 1070, Brussels, Belgium.
Cancer Radiother
February 2024
Département d'oncologie radiothérapie, institut Paoli-Calmettes, Marseille, France; Centre de recherche en cancérologie de Marseille (CRCM), Inserm UMR 1068, Marseille, France.
De novo metastatic breast cancer represents 5 to 8% of all breast cancers (2500 new cases per year in France). Systemic treatment is the cornerstone of treatment, whereas radiation therapy usually has a palliative intent. Advances in systemic and local treatments (surgery and radiation therapy) have substantially improved overall survival.
View Article and Find Full Text PDFCurr Res Transl Med
December 2023
Laboratoire de Cytogénétique Hématologique, Département d'Hématologie, CHU Timone, APHM, Aix Marseille Université, Marseille 13005, France. Electronic address:
Cytogenetic analysis is mandatory at initial assessment of B-cell acute lymphoblastic leukemia (B-ALL) due to its diagnostic and prognostic value. Results from chromosome banding analysis and complementary FISH are taken into account in therapeutic protocols and further completed by other techniques (RT-PCR, SNP-array, MLPA, NGS, OGM). Indeed, new genomic entities have been identified by NGS, mostly RNA sequencing, such as Ph-like ALL that can benefit from targeted therapy.
View Article and Find Full Text PDFMol Cancer Ther
May 2024
Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Anticancer nucleosides are effective against solid tumors and hematologic malignancies, but typically are prone to nucleoside metabolism resistance mechanisms. Using a nucleoside-specific multiplexed high-throughput screening approach, we discovered 4'-ethynyl-2'-deoxycytidine (EdC) as a third-generation anticancer nucleoside prodrug with preferential activity against diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). EdC requires deoxycytidine kinase (DCK) phosphorylation for its activity and induces replication fork arrest and accumulation of cells in S-phase, indicating it acts as a chain terminator.
View Article and Find Full Text PDFObesity and diabetes can modulate immune responses, which may impact allogeneic HCT outcomes and GvHD. From the EBMT registry, we included 36,539 adult patients who underwent allogeneic HCT for a hematological malignancy between 2016 and 2020. Of these, 5228 (14%) had obesity (BMI ≥ 30 kg/m), 1415 (4%) had diabetes (requiring treatment with insulin or oral hypoglycemics), and 688 (2%) had obesity + diabetes pre-transplantation.
View Article and Find Full Text PDFMed Dosim
May 2024
Institut Paoli-Calmettes, Service de Radiothérapie, Marseille, 13009, France.
This study exposed the implementation of a novel technique (VMAT) for the planning of moving targets in lung stereotactic body radiation therapy (SBRT). This new technique has been compared to static conformal radiotherapy (3D-CRT), volumetric-modulated arc therapy (VMAT), and dynamic conformal arc (DCA). The rationale of this study was to lower geometric complexity (54.
View Article and Find Full Text PDFBull Cancer
November 2023
Cours Saint-Paul-de-Vence, Nice, France.
With more than 60,000 new cases of breast cancer in mainland France in 2023 and 8% of all cancer deaths, breast cancer is the leading cancer in women in terms of incidence and mortality. While the number of new cases has almost doubled in 30 years, the percentage of patients at all stages alive at 5 years (87%) and 10 years (76%) testifies to the major progress made in terms of screening, characterisation and treatment. However, this progress, rapid as it is, needs to be evaluated and integrated into an overall strategy, taking into account the characteristics of the disease (stage and biology), as well as those of the patients being treated.
View Article and Find Full Text PDFN Engl J Med
December 2023
From the Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City (K.N.M.); Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris (A.A.), Aix-Marseille Université, INSERM, National Center for Scientific Research, Institut Paoli-Calmettes, Department of Medical Oncology, Marseille (R.S.), and Institut Curie, Saint-Cloud (D.B.R.) - all in France; the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles (G.E.K.); Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí, Universitat Autònoma de Barcelona, Sabadell (Y.G.), Hospital Universitario Virgen del Rocío and Instituto de Biomedicina de Sevilla, Seville (P.E.-G.), and Hospital Universitario de Jaén, Jaen (F.G.) - all in Spain; the Royal Marsden NHS Foundation Trust and Institute of Cancer Research (S.B.) and University College London Cancer Institute (S.N.) - both in London; Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of Sacred Heart, Rome (D.L.), the Gynecologic Oncology Program, European Institute of Oncology IRCCS, and the Department of Medicine and Surgery, University Milan-Bicocca, Milan (N.C.), and Dipartimento Uro-Ginecologico, Istituto Nazionale Tumori di Napoli IRCCS Fondazione G. Pascale, Naples (S.P.) - all in Italy; Yonsei University College of Medicine (J.-Y.L.) and the Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine (J.-W.L.) - both in Seoul, South Korea; the University of Chicago, Chicago (J.W.M.); Wielkopolskie Centrum Onkologii and Poznań University of Medical Sciences, Poznań, Poland (A.R.); Amsterdam University Medical Centers, Amsterdam (J.T.); Baystate Medical Center, Division of Gynecologic Oncology, University of Massachusetts-Chan Baystate, Springfield (T.M.), and ImmunoGen, Waltham (Y.W., M.M., A.B.) - both in Massachusetts; Meir Medical Center, Kfar Saba, Israel (M.B.); Ohio State University, Columbus (C.M.C.); the Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic (D.C.); the Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (L.P.M.), and Hillman Cancer Center, University of Pittsburgh, Pittsburgh (L.C.) - both in Pennsylvania; Arizona Oncology Associates, PC-HOPE, Tucson (J.B.); the University of Virginia School of Medicine, Charlottesville (L.R.D.); and University Hospital of Leuven, Leuven Cancer Institute, Leuven, Belgium (T.V.G.).
Ann Intensive Care
December 2023
Médecine Intensive Réanimation, Hôpital Saint Louis, AP-HP, Université Paris Cité, Paris, France.
EClinicalMedicine
November 2023
Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Eur J Haematol
April 2024
Département d'hématologie, CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France.
Objectives: To compare the efficacy of venetoclax-azacitidine (VEN-AZA) with AZA in the real-life for patients with first relapsed or refractory acute myeloid leukaemia (R/R AML).
Methods: We retrospectively analysed R/R AML patients treated with VEN-AZA at the Institut Paoli Calmettes between September 2020 and February 2022. We compared them to a historical cohort of patients treated with AZA between 2010 and 2021.
Adv Mater
February 2024
Aix Marseille University, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (UMR 7325), Equipe Labellisée Ligue Contre le Cancer, Marseille, 13288, France.
Bioimaging is a powerful tool for diagnosing tumors but remains limited in terms of sensitivity and specificity. Nanotechnology-based imaging probes able to accommodate abundant imaging units with different imaging modalities are particularly promising for overcoming these limitations. In addition, the nanosized imaging agents can specifically increase the contrast of tumors by exploiting the enhanced permeability and retention effect.
View Article and Find Full Text PDFLife Sci Alliance
February 2024
INSERM, CNRS, Centre D'Immunologie de Marseille-Luminy, Aix-Marseille Université, Marseille, France
VitB5 level becomes limiting in sarcomas. It is regulated by the pantetheinase activity of VNN1. VNN1 expression in sarcomas is associated with better prognosis and immune infiltration.
View Article and Find Full Text PDFAnn Gastroenterol
October 2023
Department of Gastroenterology (Fabrice Caillol, Jean-Philippe Ratone, Solène Hoibian, Yanis Dahel, Marc Giovannini).
Background: Current guidelines consider observation a reasonable strategy for G1 or G2 nonfunctional pancreatic neuroendocrine tumors (nf pNETs) ≤2 cm. We aimed to characterize their natural behavior and confront the data with the outcomes of patients undergoing upfront surgery.
Methods: Data from patients with histologically confirmed nf pNETs ≤2 cm, managed at a single tertiary referral center between 2002 and 2020, were retrospectively reviewed.
Curr Res Transl Med
December 2023
Center for Human Genetics, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium; Katholieke Universiteit Leuven, Leuven 3000, Belgium. Electronic address:
Molecular analysis is the hallmark of T-cell acute lymphoblastic leukemia (T-ALL) categorization. Several T-ALL sub-groups are well recognized based on the aberrant expression of specific transcription factors. This recently resulted in the implementation of eight provisional T-ALL entities into the novel 2022 International Consensus Classification, albeit not into the updated World Health Organization classification system.
View Article and Find Full Text PDFInsights Imaging
November 2023
Department of Interventional Radiology, Institut Paoli Calmettes, Marseille, France.
Background: To evaluate the effect of tract embolization (TE) with gelatin sponge slurries during a percutaneous lung biopsy on chest tube placement and to evaluate the predictive factors of chest tube placement.
Methods: Percutaneous CT-guided lung biopsies performed with (TE) or without (non-TE) tract embolization or between June 2012 and December 2021 at three referral tertiary centers were retrospectively analyzed. The exclusion criteria were mediastinal biopsies, pleural tumors, and tumors adjacent to the pleura without pleural crossing.
Eur J Cancer
January 2024
Institut J Godinot Reims, France.
Unlabelled: Sclerosing Epithelioid Fibrosarcoma (SEF) and Low Grade Fibromyxoid Sarcoma (LGFMS) are ultrarare sarcomas sharing common translocations whose natural history are not well known. We report on the nationwide exhaustive series of 330 patients with SEF or LGFMS in NETSARC+ since 2010.
Patients And Methods: NETSARC (netsarc.